Thin Film Electronics ASA
14.1.2021 07:05:13 CET | Globenewswire | Press release
Oslo, 14 January 2021
This disclosure is sent on behalf of certain large shareholders in Thin Film Electronics ASA (the "Company").
Reference is made to the announcement by the Company on 6 January 2021 regarding the issuance of a total of 42,552,699 shares after conversion of warrants. Due to the issuance of new shares in the Company, certain large shareholders disclose the following information pursuant to Section 4-3 of the Norwegian Securities Trading Act and the Securities Trading Act Regulations.
Upon registration, the shareholding of Tigerstaden AS and close associates will represent 9.64% of the Company's total number of outstanding shares, holding a total of 100,347,391 shares in the Company. Furthermore, Tigerstaden AS owns 45,454,545 Warrants B with an exercise price of NOK 0.25 per share and which will be exercisable at any time until 20 August 2021 and 35,083,333 Warrants C with an exercise price of NOK 0.25 per share and which will be exercisable at any time between 31 March 2021 and 30 June 2021. All unexercised Warrants will represent 7.73% of the Company's total number of outstanding shares. All shares and unexercised Warrants combined will represent 17.37% of the Company's total number of outstanding shares.
Upon registration, the shareholding of Alden AS and close associates will represent 10.93% of the Company's total number of outstanding shares, holding a total of 113,800,000 shares in the Company. Furthermore, Alden AS owns 45,454,545 Warrants B with an exercise price of NOK 0.25 per share and which will be exercisable at any time until 20 August 2021 and 40,833,333 Warrants C with an exercise price of NOK 0.25 per share and which will be exercisable at any time between 31 March 2021 and 30 June 2021. All unexercised Warrants will represent 8.29% of the Company's total number of outstanding shares. All shares and unexercised Warrants combined will represent 19.22% of the Company's total number of outstanding shares.
This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
King Faisal Specialist Hospital & Research Centre13.3.2026 22:15:53 CET | Press release
KFSH Leads Globally in Paired Kidney Transplants Performed at a Single Center in 2025
SCOR13.3.2026 18:59:39 CET | Press release
SCOR SE announces the availability of its 2025 Universal Registration Document
Novartis Pharma AG13.3.2026 18:35:19 CET | Press release
Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa
Luotea Oyj13.3.2026 18:30:00 CET | Press release
The Board of Directors of Luotea Oyj decided on updates to the company's share-based incentive plan for 2023-2027 and on the launch of a new share-based incentive plan for the years 2026-2030
Ilkka Oyj13.3.2026 18:00:00 CET | Press release
Ilkka Oyj: Acquisition of own shares on 13 March 2026
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
